65 results
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
13 Mar 24
ProQR Announces Year End 2023 Operating and Financial Results
7:10am
platform data across a variety of targets. Our platform has demonstrated robust editing, including reporting up to 70% editing of ACTB in the liver … to exercise for expansion of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR.
ProQR may selectively form new partnerships
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
19 Jan 24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
7:08am
platform data across a range of liver and CNS targets. These encouraging data and the progress of our science reinforce the potential of our Axiomer RNA
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
to advance our Axiomer RNA editing platform, with an initial focus on targets for cholestatic and cardiovascular diseases, as we seek to develop a new class
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
7 Nov 23
Current report (foreign)
10:00am
Axiomer® RNA editing platform to progress new drug targets toward clinical development and commercialization.
Under the terms of the agreement, ProQR … agreement, Lilly will gain access to additional targets in the central nervous system and peripheral nervous system with ProQR’s Axiomer platform
6-K
EX-99.2
cgxdx
7 Nov 23
Current report (foreign)
10:00am
6-K
EX-99.1
2mh5z9in0evswh wzut
27 Sep 23
ProQR Therapeutics Provides Update on Ophthalmic Assets
7:06am
6-K
EX-99.1
yisntwnk oa
3 Aug 23
Current report (foreign)
7:15am
6-K
EX-99.2
nwree4s75hy fvykba6
3 Aug 23
Current report (foreign)
7:15am
6-K
EX-99.1
utv 027iym4gdx
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
n4krf
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
EX-99.2
qy5xnh04pb70n4tde9m
16 May 23
Current report (foreign)
7:15am
6-K
EX-99.1
bvq 6pbr1
16 May 23
Current report (foreign)
7:15am
424B5
2kjnc8hr0byg1ho7aez5
24 Apr 23
Prospectus supplement for primary offering
4:30pm
F-3
bsr f518m83d2m86fgst
29 Mar 23
Shelf registration (foreign)
4:53pm
6-K
EX-10.1
ca1ksw6 a2
23 Dec 22
Current report (foreign)
7:10am
6-K
831f9qn f81q
23 Dec 22
Current report (foreign)
7:10am
6-K
EX-99.1
qm8wvn6
23 Dec 22
Current report (foreign)
7:10am
6-K
EX-99.2
gqmibfu7ylg q8fb4h
23 Dec 22
Current report (foreign)
7:10am